Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148739 · ClinicalTrials.gov registry record · Phase 4
Ensuring Access to Optimal Therapy in CF: The ENACT Study
A Phase 4 study of Cystic Fibrosis (CF), sponsored by Arkansas Children's Hospital Research Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
- 2
- Study locations
NCT07148739 is a Phase 4 study of Cystic Fibrosis (CF) that is actively recruiting participants, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 95 participants, below the 134-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07148739, a Phase 4 study of Cystic Fibrosis (CF), is actively recruiting participants, sponsored by Arkansas Children's Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Elexacaftor / Ivacaftor / Tezacaftor
- OTHER therapeutic drug monitoring
Study Locations (2)
Arkansas
- Arkansas Children's Hospital - Little Rock
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2030-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148739
The ClinicalTrials.gov registry entry for NCT07148739 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (29% lower). The listed sponsor is Arkansas Children's Hospital Research Institute, which has 97 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which Elexacaftor / Ivacaftor / Tezacaftor is the first listed.
NCT07148739 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, Washington.
Frequently Asked Questions
What is clinical trial NCT07148739 about?
NCT07148739 is a clinical study titled "Ensuring Access to Optimal Therapy in CF: The ENACT Study". This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing the...
What is the current status of trial NCT07148739?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2025-06-10. Estimated completion is 2030-12.
What conditions does trial NCT07148739 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF).
What interventions are being tested in trial NCT07148739?
The interventions under investigation include: Elexacaftor / Ivacaftor / Tezacaftor (DRUG), therapeutic drug monitoring (OTHER).
Who is sponsoring clinical trial NCT07148739?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148739 being conducted?
This trial has 2 study locations across Arkansas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
Study With Phage for CF Subjects With Pseudomonas Lung Infection
RECRUITING · Phase 2
-
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.